GT200500386A - Composicion que comprende una epotilona y metodos para producir dicha composicion - Google Patents

Composicion que comprende una epotilona y metodos para producir dicha composicion

Info

Publication number
GT200500386A
GT200500386A GT200500386A GT200500386A GT200500386A GT 200500386 A GT200500386 A GT 200500386A GT 200500386 A GT200500386 A GT 200500386A GT 200500386 A GT200500386 A GT 200500386A GT 200500386 A GT200500386 A GT 200500386A
Authority
GT
Guatemala
Prior art keywords
composition
methods
produce
epotilone
epotilones
Prior art date
Application number
GT200500386A
Other languages
English (en)
Inventor
Reer Olaf
Renz Matthias
Sachse Andreas
Sprenger Claudia
Thomsen Jens
Uffrecht Anka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500386A publication Critical patent/GT200500386A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A METODOS PARA PRODUCIR FORMULACIONES FARMACEUTICAS DE EPOTILONAS APROPIADAS PARA ADMINISTRAR POR VIA PARENTERAL, TAL COMO POR VIA INTRAVENOSA.
GT200500386A 2004-12-23 2005-12-22 Composicion que comprende una epotilona y metodos para producir dicha composicion GT200500386A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04090516A EP1674098A1 (en) 2004-12-23 2004-12-23 Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water

Publications (1)

Publication Number Publication Date
GT200500386A true GT200500386A (es) 2006-08-01

Family

ID=34928859

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500386A GT200500386A (es) 2004-12-23 2005-12-22 Composicion que comprende una epotilona y metodos para producir dicha composicion

Country Status (23)

Country Link
EP (3) EP1674098A1 (es)
JP (1) JP2008525362A (es)
KR (1) KR20070088802A (es)
CN (1) CN101137364B (es)
AR (1) AR052346A1 (es)
AU (1) AU2005318353B2 (es)
BR (1) BRPI0519441A2 (es)
CA (1) CA2591997A1 (es)
CR (1) CR9211A (es)
GT (1) GT200500386A (es)
HK (1) HK1114015A1 (es)
IL (1) IL183937A0 (es)
MX (1) MX2007007780A (es)
NO (1) NO20073772L (es)
NZ (1) NZ555989A (es)
PA (1) PA8657901A1 (es)
PE (2) PE20100240A1 (es)
RU (1) RU2416407C2 (es)
SG (1) SG161207A1 (es)
TW (1) TWI367758B (es)
UA (1) UA88182C2 (es)
UY (1) UY29307A1 (es)
WO (1) WO2006066949A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
JP6042412B2 (ja) 2011-04-28 2016-12-14 オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ 細胞毒性ジペプチドの凍結乾燥調製物
EP2928463B1 (en) 2012-10-26 2019-11-20 Oncopeptides AB Lyophilized preparations of melphalan flufenamide
CN107041886A (zh) 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19728914A1 (de) 1997-07-07 1999-01-14 Basf Ag Metallisch gefärbte Polyamide
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001512723A (ja) 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト 新規エポチロン誘導体、その製法およびその薬学的使用
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
MY125921A (en) * 1998-02-05 2006-08-30 Novartis Ag Compositions containing organic compounds
DE19820599A1 (de) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
WO1999067253A2 (en) 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
SE517641C2 (sv) 1998-07-02 2002-07-02 Sca Hygiene Prod Ab Förfarande för att framställa ett materialskikt med barriärflikar samt ett ytskikt med sådana barriärflikar
JP2002533346A (ja) 1998-12-22 2002-10-08 ノバルティス アクチエンゲゼルシャフト エポシロン誘導体およびそれらの抗腫瘍剤としての使用
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
EE200100431A (et) 1999-02-18 2002-12-16 Schering Aktiengesellschaft 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
DE19908760A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19908763A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19907588A1 (de) 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh C-21 Modifizierte Epothilone
US20020058286A1 (en) 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
AU4017400A (en) * 1999-03-29 2000-10-16 Bristol-Myers Squibb Company A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
AR023792A1 (es) * 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
WO2001064650A2 (en) 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Center Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
DE10020517A1 (de) 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US20020045609A1 (en) 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
WO2002008440A2 (en) 2000-07-25 2002-01-31 Kosan Biosciences, Inc. Fermentation process for epothilones
AU2001283275A1 (en) 2000-08-09 2002-02-18 Kosan Biosciences, Inc. Bio-intermediates for use in the chemical synthesis of polyketides
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002213248A1 (en) 2000-10-13 2002-04-22 The University Of Mississipi Synthesis of epothilones and relates analogs
WO2002032844A2 (de) 2000-10-16 2002-04-25 Morphochem Ag Epothilone-synthesebausteine iii und iv: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie verfahren zur herstellung von epothilon b, d und epothilonderivaten
PL207720B1 (pl) * 2001-01-25 2011-01-31 Bristol Myers Squibb Co Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej
HU229349B1 (en) * 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
JP2004521122A (ja) * 2001-01-25 2004-07-15 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン類似体の非経口製剤
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
WO2004032866A2 (en) * 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Therapeutic formulations
EP1670487A4 (en) * 2003-10-09 2008-05-21 Kosan Biosciences Inc THERAPEUTIC FORMULATIONS
WO2006034147A2 (en) * 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs

Also Published As

Publication number Publication date
IL183937A0 (en) 2007-10-31
TWI367758B (en) 2012-07-11
WO2006066949A1 (en) 2006-06-29
CR9211A (es) 2007-11-23
AR052346A1 (es) 2007-03-14
CN101137364B (zh) 2011-11-16
PE20060839A1 (es) 2006-09-15
SG161207A1 (en) 2010-05-27
NZ555989A (en) 2010-12-24
UA88182C2 (ru) 2009-09-25
NO20073772L (no) 2007-09-21
EP1827428A1 (en) 2007-09-05
EP2371365A1 (en) 2011-10-05
JP2008525362A (ja) 2008-07-17
HK1114015A1 (en) 2008-10-24
EP1674098A1 (en) 2006-06-28
PE20100240A1 (es) 2010-05-02
CA2591997A1 (en) 2006-06-29
PA8657901A1 (es) 2007-01-17
AU2005318353A1 (en) 2006-06-29
AU2005318353B2 (en) 2011-09-29
KR20070088802A (ko) 2007-08-29
BRPI0519441A2 (pt) 2009-01-20
MX2007007780A (es) 2007-08-14
RU2416407C2 (ru) 2011-04-20
CN101137364A (zh) 2008-03-05
TW200635586A (en) 2006-10-16
RU2007128068A (ru) 2009-01-27
UY29307A1 (es) 2006-07-31

Similar Documents

Publication Publication Date Title
HN2008001103A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
HN2008000792A (es) Compuesto de cinamida biciclico
ECSP11011054A (es) Péptidos antivirales terapéuticos
UY31274A1 (es) Composiciones de recubrimiento electrodepositable que contiene una guanidina ciclica
SV2009003392A (es) Aril pirrolidinas insecticidas
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
PA8774501A1 (es) Nueva sales y sus usos
HN2011001247A (es) Inhibidores de cinana akt y p70 s6
CR9558A (es) Formulaciones de quinina
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
CR9786A (es) Compuestos de bencimidazol-tiofeno
UY29248A1 (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO6321288A2 (es) Sales de compuestos inhibidores de vih
HN2009000856A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
GT200500386A (es) Composicion que comprende una epotilona y metodos para producir dicha composicion
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
ATE552832T1 (de) Antidepressivum-propharmaka
PA8772401A1 (es) Macrólidos
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
CR10651A (es) Derivados de feniloxianilina
NI201000139A (es) ASOCIACION DE UN INHIBIDOR DE CORRIENTE SINUSAL If Y DE UN BETA-BLOQUEANTE